|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Physiology & Biophysics, Case Western Reserve University, Cleveland, OH, USA
2 Department of Nutrition, Case Western Reserve University, Cleveland, OH, USA
3 Louis Stokes Dept of Veteran Affairs Medical Center, Medical Research Service, Cleveland, OH, USA
4 Department of Biochemistry, Case Western Reserve University, Cleveland, OH, USA
5 Department of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA; Louis Stokes Dept of Veteran Affairs Medical Center, Medical Research Service, Cleveland, OH, USA
6 Department of Medicine, Henry Ford Heart & Vascular Institute, Detroit, MI, USA
7 Department of Physiology & Biophysics, Case Western Reserve University, Cleveland, OH, USA; Department of Nutrition, Case Western Reserve University, Cleveland, OH, USA
* To whom correspondence should be addressed. E-mail: wcs4{at}po.cwru.edu.
Recent human and animal studies have demonstrated that in severe end-stage heart failure (HF), the cardiac muscle switches to a more fetal metabolic phenotype, characterized by down regulation of free fatty acid (FFA) oxidation and an enhancement of glucose oxidation. The goal of this study was to examine myocardial substrate metabolism in a model of moderate coronary microembolization-induced HF. We hypothesized that during well-compensated HF, FFA oxidation would predominate as opposed to a more fetal metabolic phenotype of greater glucose oxidation. Cardiac substrate uptake and oxidation was measured in normal dogs (n=8) and dogs with microembolization-induced HF (n=18, EF=28%) by infusing three isotopic tracers ([9,10- 3H]oleate, [U-14C]glucose and [1-13C]lactate) in anesthetized open-chest animals. There were no differences in myocardial substrate metabolism between the two groups. The total activity of pyruvate dehydrogenase, the key enzyme regulating myocardial pyruvate oxidation (and hence glucose and lactate oxidation) was not affected by HF. We did not observe any difference in the activity of carnitine palmitoyl transferase I (CPT-I) and its sensitivity to inhibition by malonyl- CoA between groups, however malonyl-CoA content was decreased by 22% with HF, suggesting less in vivo inhibition of CPT-I activity. The differences in malonyl-CoA content cannot be explained by changes in the Km and Vmax for malonyl CoA decarboxylase as neither were affected by HF. These results support the concept that there is no decrease in fatty acid oxidation during compensated HF, and that the downregulation of fatty acid oxidation enzymes and switch to carbohydrate oxidation observed in end-stage HF is only a late-stage phenomemon.
This article has been cited by other articles:
![]() |
C. Pellieux, C. Montessuit, I. Papageorgiou, and R. Lerch Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-{alpha} Cardiovasc Res, May 1, 2009; 82(2): 341 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. van Bilsen, F. A. van Nieuwenhoven, and G. J. van der Vusse Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res, February 15, 2009; 81(3): 420 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. O'Donnell, A. Fields, X. Xu, S. A. K. Chowdhury, D. L. Geenen, and J. Bi Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2483 - H2494. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Rosca, E. J. Vazquez, J. Kerner, W. Parland, M. P. Chandler, W. Stanley, H. N. Sabbah, and C. L. Hoppel Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation Cardiovasc Res, October 1, 2008; 80(1): 30 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamashita, K. G. Bharadwaj, S. Ikeda, T.-S. Park, and I. J. Goldberg Cardiac metabolic compensation to hypertension requires lipoprotein lipase Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E705 - E713. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Eisen Exercise Training and Myocardial Energetics in Patients With Heart Failure: When More Is Less J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1892 - 1895. [Full Text] [PDF] |
||||
![]() |
H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Neubauer The Failing Heart -- An Engine Out of Fuel N. Engl. J. Med., March 15, 2007; 356(11): 1140 - 1151. [Full Text] [PDF] |
||||
![]() |
J. D. Horowitz and J. A. Kennedy Time to Address the Cardiac Metabolic "Triple Whammy": Ischemic Heart Failure in Diabetic Patients J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2232 - 2234. [Full Text] [PDF] |
||||
![]() |
W.H. W. Tang Metabolic Approach in Heart Failure: Rethinking How We Translate From Theory to Clinical Practice J. Am. Coll. Cardiol., September 5, 2006; 48(5): 999 - 1000. [Full Text] [PDF] |
||||
![]() |
G. D. Lopaschuk Optimizing cardiac Fatty Acid and glucose metabolism as an approach to treating heart failure. Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 228 - 230. [Abstract] [PDF] |
||||
![]() |
A. J. Murray, C. A. Lygate, M. A. Cole, C. A. Carr, G. K. Radda, S. Neubauer, and K. Clarke Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart Cardiovasc Res, July 1, 2006; 71(1): 149 - 157. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liao, S. Takashima, H. Zhao, Y. Asano, Y. Shintani, T. Minamino, J. Kim, M. Fujita, M. Hori, and M. Kitakaze Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice Cardiovasc Res, April 1, 2006; 70(1): 107 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. King, I. C. Okere, N. Sharma, J. R. B. Dyck, A. E. Reszko, T. A. McElfresh, J. Kerner, M. P. Chandler, G. D. Lopaschuk, and W. C. Stanley Regulation of cardiac malonyl-CoA content and fatty acid oxidation during increased cardiac power Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1033 - H1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |